Cyclophosphamide

Generic Name: Cyclophosphamide

Brand Names: Procytox

Drug Type: Small Molecule

Chemical Formula: C_₇H_₁₅Cl_₂N_₂O_₂P

CAS Number: 50-18-0

Unique Ingredient Identifier: 6UXW23996M

Background: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.

Indication: Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma

Associated Therapies: -

Clinical Trials

Primary Breast Cancer Occurring Concomitant With Pregnancy

Early Phase 1

Completed

Conditions: Breast Cancer
Pregnancy

Interventions: Drug: 5-Fluorouracil
Drug: Cyclophosphamide
Drug: Doxorubicin

First Posted Date: 2007-08-02

Last Posted Date: 2020-07-10

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 61

Registration Number: NCT00510367

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Anti-gp100:154-162 TCR Gene Engineered Lymphocytes

Phase 2

Terminated

Conditions: Skin Cancer
Melanoma

Interventions: Drug: fludarabine phosphate
Drug: cyclophosphamide
Biological: aldesleukin

First Posted Date: 2007-07-31

Last Posted Date: 2013-01-15

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 21

Registration Number: NCT00509496

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Infusion of Anti-MART-1 F5 TCR-Gene-Engineered Lymphocytes

Phase 2

Completed

Conditions: Melanoma
Skin Cancer

Interventions: Biological: autologous anti-MART-1 F5 T-cell receptor
Drug: Cyclophosphamide
Drug: Fludarabine
Biological: Aldesleukin
Biological: autologous anti-MART-1 F5 T-cell receptor gene-engineered tumor infiltrating lymphocytes

First Posted Date: 2007-07-31

Last Posted Date: 2012-12-28

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 24

Registration Number: NCT00509288

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Phase 1/2 Study of VELCADE® in Combination With Other Drugs to Treat Previously Untreated Multiple Myeloma Patients

Phase 1

Completed

Conditions: Multiple Myeloma

Interventions: Drug: VELCADE (bortezomib)
Drug: dexamethasone
Drug: Revlimid (lenalidomide)
Drug: cyclophosphamide

First Posted Date: 2007-07-26

Last Posted Date: 2013-07-26

Lead Sponsor: Millennium Pharmaceuticals, Inc.

Target Recruit Count: 158

Registration Number: NCT00507442

Locations: 🇺🇸
Rocky Mountain Cancer Center, Denver, Colorado, United States
🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Autologous and Allogenic Transplantation With Campath-1H for T-Cell Lymphoma

Phase 2

Terminated

Conditions: Lymphoma

Interventions: Drug: Campath-1H
Drug: G-CSF
Drug: GM-CSF
Drug: BCNU
Drug: Stem Cell Transplant
Drug: Preparative Regimen for Allogenic Stem Cell Transplantation
Drug: Cytarabine
Drug: Etoposide
Drug: Melphalan
Drug: Campath
Drug: Fludarabine
Drug: Cyclophosphamide
Radiation: Low dose total body irradiation

First Posted Date: 2007-07-25

Last Posted Date: 2011-11-16

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 27

Registration Number: NCT00505921

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Phase 2

Recruiting

Conditions: T Acute Lymphoblastic Leukemia
T Lymphoblastic Lymphoma

Interventions: Drug: Cyclophosphamide
Drug: Cytarabine
Drug: Dexamethasone
Drug: Doxorubicin Hydrochloride
Drug: Mercaptopurine
Drug: Methotrexate
Drug: Nelarabine
Drug: Pegaspargase
Drug: Prednisone
Drug: Venetoclax
Drug: Vincristine Sulfate

First Posted Date: 2007-07-16

Last Posted Date: 2024-12-16

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 160

Registration Number: NCT00501826

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Treatment of Tumors of the Choroid Plexus Epithelium

Phase 3

Terminated

Conditions: Choroid Plexus Tumors

Interventions: Drug: Carboplatin
Drug: Cyclophosphamide
Drug: Etoposide
Drug: Vincristine
Radiation: Radiation Therapy

First Posted Date: 2007-07-13

Last Posted Date: 2020-02-27

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 2

Registration Number: NCT00500890

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Paclitaxel Followed by FEC Versus Paclitaxel and RAD001 Followed by FEC In Women With Breast Cancer

Phase 2

Conditions: Breast Cancer

Interventions: Drug: Paclitaxel
Drug: 5-Fluorouracil
Drug: Epirubicin
Drug: Cyclophosphamide
Drug: RAD001

First Posted Date: 2007-07-11

Last Posted Date: 2016-11-01

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 62

Registration Number: NCT00499603

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Combination Chemotherapy and Surgery With or Without Isotretinoin in Treating Young Patients With Neuroblastoma

Phase 3

Completed

Conditions: Neuroblastoma

Interventions: Drug: carboplatin
Drug: cyclophosphamide
Drug: doxorubicin hydrochloride
Drug: etoposide
Drug: topotecan hydrochloride
Procedure: Surgery
Drug: Isotretinoin
Drug: Filgrastim

First Posted Date: 2007-07-11

Last Posted Date: 2021-07-06

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 464

Registration Number: NCT00499616

Locations: 🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸
St. Christopher's Hospital for Children, Philadelphia, Pennsylvania, United States
🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States

and more 186 locations

NOV-002, Doxorubicin, Cyclophosphamide, and Docetaxel in Women With Newly Diagnosed Stage II or IIIC Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: Cyclophosphamide
Drug: Docetaxel
Drug: Doxorubicin
Drug: NOV 002

First Posted Date: 2007-07-11

Last Posted Date: 2018-01-02

Lead Sponsor: University of Miami

Target Recruit Count: 41

Registration Number: NCT00499122

Locations: 🇺🇸
Hollings Cancer Center at Medical University of South Carolina, Charleston, South Carolina, United States
🇺🇸
University of Miami, Miami, Florida, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy